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ABSTRACT
OBJECTIVE
To investigate the association between alcohol 
consumption (at baseline and over lifetime) and 
non-fatal and fatal coronary heart disease (CHD) and 
stroke.
DESIGN
Multicentre case-cohort study.
SETTING
A study of cardiovascular disease (CVD) determinants 
within the European Prospective Investigation into 
Cancer and nutrition cohort (EPIC-CVD) from eight 
European countries.
PARTICIPANTS
32 549 participants without baseline CVD, 
comprised of incident CVD cases and a subcohort for 
comparison.
MAIN OUTCOME MEASURES
Non-fatal and fatal CHD and stroke (including 
ischaemic and haemorrhagic stroke).
RESULTS
There were 9307 non-fatal CHD events, 1699 fatal 
CHD, 5855 non-fatal stroke, and 733 fatal stroke. 
Baseline alcohol intake was inversely associated 
with non-fatal CHD, with a hazard ratio of 0.94 (95% 
confidence interval 0.92 to 0.96) per 12 g/day higher 
intake. There was a J shaped association between 
baseline alcohol intake and risk of fatal CHD. The 
hazard ratios were 0.83 (0.70 to 0.98), 0.65 (0.53 to 
0.81), and 0.82 (0.65 to 1.03) for categories 5.0-14.9 
g/day, 15.0-29.9 g/day, and 30.0-59.9 g/day of total 
alcohol intake, respectively, compared with 0.1-4.9 g/
day. In contrast, hazard ratios for non-fatal and fatal 
stroke risk were 1.04 (1.02 to 1.07), and 1.05 (0.98 
to 1.13) per 12 g/day increase in baseline alcohol 
intake, respectively, including broadly similar findings 
for ischaemic and haemorrhagic stroke. Associations 
with cardiovascular outcomes were broadly similar 
with average lifetime alcohol consumption as 
for baseline alcohol intake, and across the eight 
countries studied. There was no strong evidence for 
interactions of alcohol consumption with smoking 
status on the risk of CVD events.
CONCLUSIONS
Alcohol intake was inversely associated with non-fatal 
CHD risk but positively associated with the risk of 
different stroke subtypes. This highlights the opposing 
associations of alcohol intake with different CVD types 
and strengthens the evidence for policies to reduce 
alcohol consumption.
Introduction
Cardiovascular disease (CVD) is a leading cause of 
mortality worldwide, and it is estimated that the 
overall number of cardiovascular disease deaths will 
rise to 20 million by 2030.1 Coronary heart disease 
(CHD) and stroke are the most common forms of CVD, 
as estimated by the Global Burden of Disease study.2 
CHD and stroke account for 20% and 12% respectively 
of overall mortality in Europe.3 The association 
between alcohol consumption and the risk of CVD has 
been investigated. A positive association with stroke 
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WhAT IS AlReAdy knoWn on ThIS TopIC
Most prospective studies solely assessed recent alcohol intake at the time of 
entry into a cohort 
Moderate alcohol consumption has been associated with a lower risk of coronary 
heart disease (CHD), as well as a higher risk of cancer and all cause mortality 
Alcohol consumption has been associated with a higher risk of total stroke, but 
evidence about stroke subtypes is limited
WhAT ThIS STudy AddS 
Associations with cardiovascular outcomes were broadly similar with average 
lifetime alcohol consumption as for baseline alcohol intake
Alcohol intake was inversely associated with the risk of non-fatal CHD, but 
there were positive and broadly similar associations with risk of ischaemic and 
haemorrhagic stroke
Given the known positive association of alcohol intake with all cause mortality 
and the risk of cancer, the opposing associations of alcohol intake we found with 
different cardiovascular disease types strengthen the rationale for policies to 
reduce alcohol consumption 
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has been established, but the shapes of dose-response 
relations for different CVD outcomes have not been 
well characterised.4
Epidemiological studies have provided observational 
evidence of lower risk of CHD with moderate alcohol 
consumption compared with non-drinkers and heavy 
drinkers. The existence of a J shaped relation between 
alcohol intake and the risk of CHD was reported in a 
meta-regression study.5 Lower risk of CHD in regular 
drinkers and higher risk of CHD in binge and heavy 
drinkers, compared with non-drinkers, was described 
in a subsequent meta-analysis.6 Those results were 
recently confirmed in a meta-analysis of 11 cohort 
studies, which reported that baseline alcohol intake 
in the range of 15-30 g/day was inversely related with 
the risk of CHD, compared with non-drinkers.7 It has 
also been suggested that non-fatal and fatal CHD 
might have different determinants.8 Investigations 
focusing on fatal CHD events tended to report positive 
associations with alcohol intake compared with studies 
that evaluated the association between alcohol intake 
and both non-fatal and fatal CHD events.9 A meta-
analysis of cohort and case-control studies reported 
that alcohol intake was consistently associated with 
a higher risk of morbidity and mortality of ischaemic 
and haemorrhagic stroke, in both men and women.10 
In a recent study in the UK, heavy alcohol intake 
was positively associated with coronary death, heart 
failure, cardiac arrest, transient ischaemic attack, 
ischaemic stroke, intracerebral haemorrhage, and 
peripheral arterial disease, compared with moderate 
use, but inversely related to myocardial infarction or 
stable angina.4 Such opposing relations of alcohol 
consumption with different CVD types have also been 
reported in a recent study combined analysis of data 
from 83 cohorts in high-income countries.11
Most prospective studies of CVD have solely 
assessed recent alcohol intake at participants’ time 
of entry into a cohort, but not queried participants’ 
drinking habits over many earlier decades (ie, lifetime 
alcohol consumption). Similarly, the association 
between consumption of different types of alcohol 
(eg, wine and beer) and CVD risk has not been 
thoroughly explored. Hence, we evaluated the dose-
response association of baseline and lifetime alcohol 
consumption, including different types of alcohol, 
with the risk of incident CHD and stroke in the EPIC-
CVD study.
Methods
Study population and design
The European Prospective Investigation into Cancer 
and nutrition (EPIC) study enrolled 519 978 adults 
(366 521 women) aged mostly 35-70 from 23 centres 
in 10 countries between 1991 and 2000, as described 
elsewhere.12 EPIC-CVD is a multi centre case-cohort 
study nested within the EPIC cohort designed to 
investigate the determinants of cardiovascular disease 
(CVD).13 The study included 18 816 incident CVD cases 
identified between March 1991 and December 2010 
in the EPIC cohort and a random subcohort of 17 634 
EPIC participants was used as a reference group.14 
Participants in the case-cohort study belonged to one 
of the following categories: cases that arose outside the 
subcohort, cases that arose in the subcohort, and non-
cases in the subcohort.
Outcome assessment
The main coronary disease endpoints were defined 
as any coronary heart disease (CHD), comprised 
of myocardial infarction (ICD-10 (international 
classification of diseases, 10th revision) codes: 
I21, I22), angina (I20), or other CHD (I23-I25). 
Cerebrovascular events were ascertained and validated 
using the same methods as for coronary events and 
included haemorrhagic stroke (I60-I61), ischaemic 
stroke (I63), unclassified stroke (I64), and other acute 
cerebrovascular events (I62, I65-69, F01). Non-fatal 
coronary events were ascertained by different methods 
depending on the follow-up procedures used by each 
centre, using active follow-up through questionnaires 
or linkage with morbidity and hospital registries, or 
both.13
Validation of suspected events was performed on all 
ascertained case events (Italy, Spain, Greece, Germany, 
and Denmark) or on a subset of events (UK, the 
Netherlands, and Sweden). Validation was performed 
by retrieving and assessing medical records or hospital 
notes, contact with medical professionals, retrieving 
and assessing death certificates, or verbal autopsy. 
Angina was not assessed as a CHD outcome in the 
Italian EPIC centres of Varese, Torino, and in Germany, 
Sweden, and Denmark. To harmonise the definition 
of fatal CVD across centres, non-fatal and fatal events 
occurring within 28 days of each other were considered 
to be a single fatal event, in accordance with commonly 
used definitions.15 Information on CVD and overall 
mortality were ascertained using boards of health and 
mortality registries (Italy, Spain, UK, the Netherlands, 
Sweden, and Denmark) or by active follow-up (Greece 
and Germany). In the EPIC study, loss to follow-up is 
less than 0.3%.
Participant characteristics
We calculated alcohol consumption at baseline 
for the whole EPIC cohort from validated dietary 
questionnaires specific to each country which 
captured local dietary habits.12 16 Participants reported 
the number of standard glasses of wine, beer, cider, 
sweet liquor, distilled spirits, or fortified wines they 
consumed daily or weekly during the 12 months 
before recruitment. Alcohol consumption was taken 
from highly standardised 24 hour dietary recall 
measurements from a subset of the cohort.17
We calculated total alcohol intake using the 
estimated ethanol content in the types of alcohol 
and information on average glass volumes for each 
country. Lifetime alcohol consumption, available 
for 76% of participants (395 183/519 978), was 
assessed as glasses of different beverages consumed 
weekly at age 20, 30, 40, and 50. Average lifetime 
alcohol consumption was determined as a weighted 
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average of intake over lifetime, with weights equal to 
the time of individual exposure to alcohol at different 
ages.18 Smoking status at baseline, age at starting and 
quitting smoking, and number of cigarettes smoked 
daily was collected by lifestyle questionnaires for each 
country. The following information was also collected: 
socioeconomic status, height and weight (self reported 
in the UK Oxford centre, measured elsewhere), 
physical activity, and history of previous illnesses 
(including myocardial infarction, angina, stroke, 
diabetes, cancer, and hypertension). Participants from 
Norway and France were excluded as there were too 
few cardiovascular events in these countries to obtain 
reliable estimates. 
Statistical analyses
After exclusion of participants with missing values 
for smoking variables (n=505), baseline alcohol 
consumption (51), body mass index (273), physical 
activity (333), and history of hypertension (1112), 
32 549 participants (52% women, 17 015/32 549), 
remained in the analysis. Predefined categories of 
baseline and lifetime alcohol intakes were defined 
as lower than 0.1 g/day (defined as non-drinkers at 
baseline and never drinkers at lifetime), 0.1–4.9 g/
day (reference category), 5.0-14.9 g/day, 15.0-29.9 g/
day, 30.0-59.9 g/day, and ≥60.0 g/day. Associations for 
wine and beer intake (each grouped into non-drinkers, 
0.1–2.9 g/day (reference), 3.0-9.9 g/day, 10.0-19.9 g/
day, 20.0-39.9 g/day, and ≥40.0 g/day, ≥20.0 g/day in 
women) were assessed in mutually adjusted models, 
also accounting for spirits, liquors, and fortified wine 
intake. 
The first non-fatal and fatal CHD and stroke events 
were modelled in Prentice weighted Cox proportional 
hazard models with age as the underlying time 
variable,19 stratified by sex and centre. Participants 
within the subcohort contributed follow-up time until 
the point at which they had a non-fatal or fatal CVD 
event, died of a non-CVD cause, were lost to follow-up, 
or reached the end of the centre’s follow-up period. 
Robust standard errors were used since participants’ 
contributions to the case-cohort pseudo-likelihood are 
not independent.20 Models were adjusted for age at 
recruitment; body mass index; height; smoking status 
categorised as never (reference category), former, 
and current; history of hypertension (yes or no); and 
physical activity as defined by the Cambridge Index 
(inactive, moderately inactive, moderately active, and 
active). Adjustment for more extensive information 
on smoking frequency and duration, plasma levels of 
total cholesterol, high density lipoprotein cholesterol, 
triglycerides at baseline, and education level did not 
alter the risk estimates; these results were not retained 
further.
Hazard ratios for overall CVD and non-fatal and fatal 
CHD and stroke were computed in relation to baseline 
and lifetime alcohol consumption in predefined 
categories, per 12 g/day increase, and for mutually 
adjusted types of alcohol. In analyses of lifetime 
alcohol consumption, information on alcohol intake 
at different ages was used to separate non-drinkers at 
baseline into never drinkers and former drinkers. We 
conducted sensitivity analyses, in turn, for non-fatal 
CHD and stroke after exclusion of the first two years of 
follow-up (to help limit potential reverse causality), for 
non-fatal and overall myocardial infarction, separately 
in centres that collected information on incident 
angina, and by adjusting models for known history of 
cancer and diabetes. We conducted further analyses 
separately for ischaemic and haemorrhagic stroke.
The overall test of significance for the association 
of alcohol consumption with CVD outcomes was 
assessed with Wald test statistics compared with 
a χ2 distribution with degrees of freedom equal to 
the number of categories minus one, not including 
the non-drinker category. We performed trend tests 
by modelling alcohol consumption as a continuous 
variable on the log hazard scale, with inclusion of an 
indicator variable to define non-drinkers. A quadratic 
term for alcohol intake was also included in the model 
for fatal CHD to assess non-linearity. We further 
investigated the shape of the association between 
alcohol consumption and risk of non-fatal CHD using 
restricted cubic splines with knots defined by the mid-
points of categories described earlier.
We evaluated potential heterogeneity of associations 
between alcohol consumption and the risk of non-
fatal CHD and stroke according to smoking status 
by including an interaction term between baseline 
alcohol consumption (continuous) and smoking 
status (0=never, 1=current smokers). We assessed 
the interaction term with the Wald test on one degree 
of freedom. We also evaluated the heterogeneity of 
associations by physical activity and education level, 
but the results were compatible with the hypothesis 
of homogeneity across levels of these variables. 
The assumption of proportionality of hazards was 
evaluated using the inclusion into the disease model of 
interaction terms between exposure and attained age 
(data not shown).
The certainty of each incident cardiovascular event 
was assessed using available clinical information, and 
a score was developed to express low, medium, or high 
certainty, as summarised in supplementary table 5. We 
excluded events with the lowest certainty level when 
performing the sensitivity analyses and effect estimates 
were minimally affected, even for fatal stroke.
Hazard ratios for the associations of non-fatal and 
fatal CHD and stroke with baseline alcohol consumption 
(per 12 g/day increase) were further estimated for each 
country and combined with random effects meta-
analyses. Linear and quadratic terms were modelled 
for fatal CHD. Heterogeneity by country was assessed 
with the Cochran Q test, and estimated by the I2 index. 
We obtained the associated P value by comparing the 
Cochran Q statistics to a χ2 distribution with degrees 
of freedom equal to the number of countries minus 
one. Statistical tests were two sided, and P values less 
than 0.05 were considered statistically significant. 
All analyses were performed using Stata version 12 
(StataCorp, College Station, TX).21
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Patient involvement
No participants were involved in setting the research 
question or the outcome measures, nor were 
they involved in developing plans for design or 
implementation of the study. No participants were 
asked to advise on interpretation or writing up of 
results. There are no plans to disseminate the results 
of the research to study participants or the relevant 
patient community.
Results
Baseline characteristics
Table 1 shows the sex and country specific numbers of 
cardiovascular events, as well as descriptive statistics 
about baseline and lifetime alcohol consumption, 
including types of alcohol, among the subcohort. A 
total of 11 006 first coronary heart disease (CHD) events 
were identified; 9307 were non-fatal and 1699 were 
fatal. A total of 6588 first stroke events were identified; 
5855 were non-fatal and 733 were fatal. The median 
age at recruitment and follow-up time in the subcohort 
were 52 and 12.5 years, respectively.
Baseline and lifetime alcohol consumption averages 
among alcohol drinkers in the subcohort were, 
respectively, 24 g/day and 30 g/day in men, and 
10 g/day and 8 g/day in women. Baseline alcohol 
consumption in men was higher in Italy, Spain, 
Germany, and Denmark than in other EPIC countries. 
Women from Denmark had the highest baseline 
and lifetime alcohol intake. Wine represented more 
than 50% of total alcohol intake; beer represented 
around 30% and 20% of total intake, in men and 
women, respectively. This pattern of consumption was 
relatively homogeneous across countries for women. 
In Italy and Spain men mainly consumed wine, but in 
Germany they mainly consumed beer. The subcohort is 
described by categories of alcohol intake and smoking 
status in supplementary table 1. Average baseline 
alcohol consumption was consistently higher, for men 
and women, in former and current smokers than in 
never smokers.
Alcohol consumption, coronary heart disease, 
and stroke
Alcohol consumption was inversely associated 
with non-fatal CHD (hazard ratio of 0.94 per 12 g/
day increase, 95% confidence interval 0.91 to 0.96, 
P<0.001 for trend). Table 2 shows that compared with 
the reference group (0.1-4.9 g/day), alcohol drinkers 
of 30.0-59.9 g/day and at least 60.0 g/day had hazard 
ratios of to 0.73 (95% confidence interval 0.65 to 0.83) 
and 0.68 (0.57 to 0.81), respectively, for non-fatal 
CHD. Alcohol was non-linearly associated with fatal 
CHD, with hazard ratios for the 15.0-29.9 g/day group 
as low as 0.65 (0.53 to 0.81), and up to 0.98 (0.70 to 
1.37) for intakes greater than 60.0 g/day. The non-
linear association between alcohol intake and fatal 
CHD was described by a quadratic model with hazard 
ratio per 12 g/day increase indicating first and second 
degree terms equal to, respectively, 0.92 (0.85 to 0.99) 
and 1.01 (1.00 to 1.02). Figure 1 shows the non-linear 
trends from a restricted cubic splines analysis. Baseline 
alcohol consumption was positively associated with 
non-fatal stroke (hazard ratio of 1.04 per 12 g/day 
increase, 95% confidence interval 1.02 to 1.07), 
while the association with fatal stroke was of similar 
magnitude but not statistically significant (1.05, 
0.98 to 1.13). Positive associations with overlapping 
confidence intervals were observed for ischaemic and 
haemorrhagic stroke, with hazard ratio of 1.05 per 12 
Table 1 | Sex and country specific numbers of cardiovascular events (n=17 594) and descriptive statistics about baseline and lifetime alcohol status 
and consumption (g/day) among the subcohort (n=16 244)
Country Total events
CHD Stroke Baseline alcohol Lifetime alcohol Types of alcohol 
Non-fatal Fatal Non-fatal Fatal
Non- 
drinkers (%) Drinkers*
Never  
drinkers (%) Drinkers* Wine Beer Spirits†
Men
Italy 622 472 25 115 10 5 26 (1-65) 3 24 (2-60) 22 (0-59) 1 (0-5) 2 (0-11)
Spain 1265 797 93 343 32 13 33 (2-88) 3 46 (3-111) 26 (0-73) 3 (0-16) 4 (0-17)
UK 1568 1042 292 161 73 11 11 (1-39) 1 14 (1-38) 5 (0-29) 4 (0-22) 2 (0-8)
The Netherlands 498 385 31 75 7 10 18 (1-55) NA NA 3 (0-14) 9 (0-35) 3 (0-22)
Greece 399 177 62 104 56 9 20 (1-67) 5 32 (0-96) 10 (0-43) 4 (0-19) 6 (0-28)
Germany 761 383 93 263 22 4 26 (2-68) 1 29 (3-76) 8 (0-44) 15 (0-60) 2 (0-7)
Sweden 2763 1220 407 1,057 79 11 11 (1-36) NA NA 3 (0-12) 4 (0-12) 4 (0-16)
Denmark 2158 1055 154 922 27 2 29 (2-78) 1 21 (3-51) 11 (0-30) 14 (0-55) 4 (0-11)
All 10 034 5531 1157 3040 306 8 24 (1-70) 2 30 (2-87) 13 (0-51) 7 (0-32) 3 (0-15)
Women
Italy 596 403 10 160 23 23 11 (0-36) 16 8 (1-23) 9 (0-35) 1 (0-3) 1 (0-11)
Spain 630 311 23 260 36 50 9 (0-30) 37 7 (0-22) 7 (0-30) 1 (0-8) 0 (0-17)
UK 1233 780 142 203 108 16 7 (0-29) 6 7 (0-22) 5 (0-12) 1 (0-4) 2 (0-8)
The Netherlands 1444 986 67 321 70 20 11 (0-37) 11 9 (1-24) 6 (0-24) 1 (0-3) 4 (0-22)
Greece 271 87 30 91 63 36 6 (1-18) 34 5 (0-17) 3 (0-12) 1 (0-6) 1 (0-28)
Germany 318 112 23 172 11 5 10 (0-36) 3 7 (1-23) 7 (0-26) 2 (0-14) 1 (0-7)
Sweden 1866 641 187 950 88 18 7 (0-21) NA NA 3 (0-12) 1 (0-5) 2 (0-16)
Denmark 1202 456 60 658 28 2 14 (1-41) 6 9 (1-24) 6 (0-30) 3 (0-12) 2 (0-11)
All 7560 3776 542 2815 427 24 10 (0-33) 15 8 (0-23) 6 (0-27) 2 (0-7) 2 (0-7)
NA=Information on lifetime consumption not available in Bilthoven (The Netherlands), Naples (Italy), and Sweden.
*Mean and 5th-95th centile values calculated among drinkers only.
†Spirits, liquors, and fortified wine.
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g/day increase (95% confidence interval 1.02 to 1.09, 
P=0.001 for trend) and 1.10 (1.04 to 1.15, P<0.001 for 
trend), respectively (see supplementary table 3).
Table 3 shows that lifetime alcohol consumption 
was inversely associated with non-fatal CHD, with 
hazard ratios of 0.74 (95% confidence interval 0.64 to 
0.86) and 0.75 (0.62 to 0.91) for alcohol consumption 
of 30.0-59.9 g/day and at least 60.0 g/day, respectively, 
compared with the reference category. Lifetime alcohol 
consumption was positively associated with non-fatal 
stroke with a hazard ratio of 1.03 (95% confidence 
interval 1.00 to 1.06, P=0.03 for trend). Never and 
former drinkers had similar non-fatal CHD and stroke 
risks, showing on average a 20% higher risk compared 
with light drinkers (0.1-4.9 g/day).
Alcohol types
Table 4 shows that wine and beer intake were inversely 
associated with non-fatal CHD, with a hazard ratio of 
0.94 per 12 g/day increase (95% confidence interval 
0.91 to 0.97, P<0.001 for trend) and 0.94 (0.89 to 
0.99, P=0.013 for trend), respectively. Beer intake 
was positively associated with non-fatal stroke with 
a 7% higher risk associated per 12 g/day (3% to 
12%, P=0.002 for trend), but wine intake was not 
statistically significant. Spirits, liquors, and fortified 
wine intakes were not associated with CHD or stroke 
(data not shown).
Interaction with smoking
Smoking was associated with all cardiovascular 
disease events, with stronger hazard ratio estimates 
comparing current to never smokers observed for 
fatal CHD (hazard ratio 2.97, 95% confidence interval 
2.53 to 3.50) and non-fatal CHD (2.24, 2.05 to 2.45) 
than stroke (1.76, 1.61 to 1.92). A test for interaction 
between alcohol intake and smoking was of borderline 
statistical significance for non-fatal stroke (P=0.02), 
but there was no evidence of such an interaction for 
non-fatal CHD (P=0.46), as reported in supplementary 
table 2.
Sensitivity analyses
After exclusion of the first two years of follow-up, the 
associations between baseline alcohol consumption 
and non-fatal CHD and stroke were little changed, as 
shown in supplementary table 4. Alcohol consumption 
had inverse associations of similar magnitude with 
non-fatal and overall myocardial infarction. The 
inverse association for non-fatal myocardial infarction 
was confirmed in centres that did not assess incident 
angina, with a hazard ratio of 0.91 per 12 g/day 
increase (95% confidence interval 0.88 to 0.94, 
P<0.001 for trend). In centres that assessed angina 
the associations were weaker, with a hazard ratio of 
0.97 per 12 g/day increase (0.93 to 1.01, P=0.100 for 
trend). Further adjustment for known history of cancer 
and diabetes at baseline did not appreciably change 
the results (data not shown). Analyses by country 
indicated that the associations between baseline 
alcohol consumption and risk of non-fatal and fatal 
CHD and stroke were not materially different across 
countries (see supplementary figure 1).
discussion
The association between alcohol consumption and the 
risk of incident non-fatal and fatal coronary heart disease 
(CHD) and stroke was evaluated among individuals 
without cardiovascular disease (CVD) at baseline 
in eight European countries in the EPIC-CVD study. 
While baseline and lifetime alcohol consumption were 
inversely associated with non-fatal CHD risk, alcohol 
intake was positively associated with non-fatal stroke.
In this study, wine intake and beer intake had 
broadly similar inverse associations with non-fatal 
CHD. By contrast, beer intake was positively associated 
with the risk of non-fatal stroke while its association 
with wine intake was unclear. Country specific hazard 
ratio estimates for risk of stroke in predominantly wine 
consuming countries (eg, Italy) were similar to hazard 
ratios in predominantly beer consuming countries (eg, 
Germany and Denmark), arguing against confounding 
by geographical region. These findings are consistent 
with evidence from a meta-analysis evaluating the 
relation between types of alcohol and non-fatal and 
fatal cardiovascular outcomes.22 Wine intake has been 
associated with lower oxidative stress levels, putatively 
through the activity of antioxidants found in wine 
such as polyphenols.23-25 However, in the EPIC study 
information on the type of wine consumed (ie, red or 
white) is not available.
In our analysis, smoking was strongly positively 
associated with the risk of CHD and stroke, which is 
Table 2 | Number of events and hazard ratios for coronary heart disease and stroke by 
levels of baseline alcohol consumption (g/day)
Characteristic
Non-fatal Fatal
Events Hazard ratio (95% CI) Events Hazard ratio (95% CI)
Coronary heart disease 
Non-drinkers 1592 1.15 (1.03 to 1.28) 332 1.25 (1.01 to 1.53)
0.1-4.9 2797 1 (ref) 497 1 (ref)
5.0-14.9 2207 0.82 (0.75 to 0.90) 418 0.83 (0.70 to 0.98)
15.0-29.9 1324 0.78 (0.70 to 0.87) 198 0.65 (0.53 to 0.81)
30.0-59.9 1027 0.73 (0.65 to 0.83) 174 0.82 (0.65 to 1.03)
≥60.0 360 0.68 (0.57 to 0.81) 80 0.98 (0.70 to 1.37)
P value* <0.001 0.002
12 g/day increase Linear 0.94 (0.92 to 0.96) Linear 0.92 (0.85 to 0.99)
Quadratic 1.01 (1.00 to 1.02)
P value for trend† <0.001 P value‡ 0.003
Stroke
Non-drinkers 924 1.26 (1.12 to 1.43) 187 1.41 (1.12 to 1.79)
0.1-4.9 1573 1 (ref) 214 1 (ref)
5.0-14.9 1508 1.03 (0.93 to 1.14) 167 1.04 (0.83 to 1.31)
15.0-29.9 872 1.08 (0.96 to 1.22) 88 1.07 (0.81 to 1.42)
30.0-59.9 704 1.10 (0.96 to 1.26) 61 1.20 (0.87 to 1.67)
≥60.0 274 1.31 (1.07 to 1.60) 16 1.14 (0.65 to 2.01)
P value* 0.109 0.863
12 g/day increase Linear 1.04 (1.02 to 1.07) Linear 1.05 (0.98 to 1.13)
P value for trend† 0.002 0.136
Models were stratified by centre and sex, and systematic adjustment was undertaken for age at recruitment, body 
mass index, height, physical activity, smoking status, and history of hypertension.
*P value for the Wald test statistics compared with a χ2 distribution with four degrees of freedom, not including 
the category of non-drinkers (<0.1 g/day).
†P value for baseline alcohol consumption modelled as a continuous variable, with inclusion in the model of an 
indicator variable expressing alcohol consumption at baseline.
‡P value for inclusion of a quadratic term for baseline alcohol consumption.
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consistent with existing evidence.26-28 In line with 
previous observations,29 30 our findings suggested that 
alcohol consumption and smoking have independent 
associations with the risk of non-fatal CHD. 
Strengths and weaknesses of this study
This is the first population based study assessing the 
association between baseline and lifetime alcohol 
consumption and the risk of non-fatal and fatal CHD 
and stroke in a pan-European prospective investigation. 
Our findings reinforce previous evidence of the 
association between alcohol consumption and the 
risk of CHD in the Spanish population.31 Our analysis 
included a comparatively large number of incident 
CHD and stroke events (after exclusion of prevalent 
CVD at baseline), and controlled for several potential 
confounding factors. We harmonised exposure data 
across participating countries on alcohol consumption, 
smoking status, and other lifestyle characteristics, and 
studied validated CVD outcomes. 
A controversial element in the evaluation of the 
association between alcohol consumption and CVD 
has been the observation that non-drinkers (<0.1 g/
day) are at higher risk of CVD than moderate drinkers. 
We adopted several approaches to help limit potential 
bias involved in the study of never-drinkers (who 
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Fig 1 | Association between baseline alcohol consumption (g/day) and risk of cardiovascular disease, stroke, non-fatal 
coronary heart disease, and fatal coronary heart disease
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might differ systematically from drinkers in ways that 
are difficult to measure, but which might be relevant 
to disease causation) and of ex-drinkers (a category 
that includes people who might have abstained from 
alcohol owing to poor health itself, as well as those who 
changed their habits to achieve a healthier lifestyle).32 
33 Firstly, we studied lifetime alcohol consumption 
(available for 76% of study participants) to help limit 
the potentially distorting effects of changes in alcohol 
intake due to pre-existing morbid conditions at the 
baseline survey. Secondly, statistical tests and dose-
response relations were evaluated on current alcohol 
drinkers, and light alcohol drinkers (0.1-4.9 g/day) 
were consistently set as the reference category. Thirdly, 
in analyses on lifetime alcohol consumption, former 
and never drinkers were separated out, yet showed 
similar non-fatal CHD and stroke risks compared with 
baseline light drinkers (see supplementary table 2). 
Lastly, we showed our results were robust to a variety 
of additional sensitivity analyses, including the 
exclusion of the first two years of follow-up (to limit 
potential reverse causation), additional adjustment for 
baseline history of cancer and diabetes, and exclusion 
of participants with a history of angina. 
Nevertheless, our study had potential limitations. 
Despite attempts to control for many confounders, 
residual confounding could still affect the observed 
associations, particularly owing to factors related to 
socioeconomic status, which are difficult to assess. 
In the EPIC study, alcohol measurements at baseline 
showed relatively high validity,16 but we cannot 
discount the possibility of misclassification of alcohol 
intake (for example, under-reporting). Our study 
could not investigate the relevance of specific drinking 
patterns, such as binge drinking or regular drinking 
during meals. Large studies in progress in East Asian 
populations, where common genetic variants predict 
20-fold differences in drinking prevalence, should 
help to clarify whether alcohol intake is causally or 
artefactually associated with CVD outcomes.34
Comparison with other studies
Although a previous cohort-wide analysis of the EPIC 
study reported no strong association between lifetime 
alcohol consumption and cardiovascular mortality, 
that analysis included four times fewer cardiovascular 
outcomes than the present analysis and did not consider 
non-fatal events.30 Data from the EPIC-CVD case-cohort 
study have contributed to a recent combined analysis 
of 83 prospective studies. In contrast with the current 
study, however, that combined analysis could not 
focus systematically on lifetime alcohol consumption 
or on different types of alcohol consumed.11 In a meta-
analysis of 26 epidemiological studies (17 cohort and 
9 case-control) on stroke morbidity and mortality, 
alcohol intake was positively associated with the risk 
of haemorrhagic and ischaemic stroke, similarly in 
men and women.10 In a large recent study conducted 
in the UK, heavy drinkers (defined as participants 
exceeding current UK guidelines for alcohol of 24 g/
day and 16 g/day, for men and women respectively) 
compared with moderate drinkers (within the UK 
alcohol guidelines) showed hazard ratio estimates 
of 1.21 (95% confidence interval 1.08 to 1.35) for 
coronary heart death, 1.22 (1.08 to 1.37) for heart 
failure, 1.50 (1.26 to 1.77) for cardiac arrest, 1.11 
(1.02 to 1.37) for transient ischaemic attack, 1.33 
(1.09 to 1.63) for ischaemic stroke, 1.37 (1.16 to 1.62) 
for intracerebral haemorrhage, 1.35 (1.23 to 1.48) for 
peripheral arterial disease, and 0.88 (0.79 to 1.00) for 
myocardial infarction.4
Table 3 | Number of events and hazard ratios for non-fatal coronary heart disease (CHD) 
and non-fatal stroke by levels of lifetime alcohol consumption (g/day), accounting for 
former drinkers
Characteristic
Non-fatal CHD Non-fatal stroke
Events Hazard ratio (95% CI) Events Hazard ratio (95% CI)
Former drinkers* 615 1.24 (1.05 to 1.46) 253 1.27 (1.04 to 1.54)
Never drinkers 580 1.17 (1.00 to 1.38) 305 1.14 (0.95 to 1.37)
0.1-4.9 1571 1 (ref) 791 1 (ref)
5.0-14.9 1800 0.89 (0.80 to 1.00) 1024 0.98 (0.86 to 1.11)
15.0-29.9 1102 0.79 (0.69 to 0.90) 685 1.01 (0.87 to 1.17)
30.0-59.9 698 0.74 (0.64 to 0.86) 428 1.08 (0.90 to 1.30)
≥60.0 331 0.75 (0.62 to 0.91) 179 1.12 (0.88 to 1.44)
P value† <0.001 0.736
12 g/day increase 0.97 (0.94 to 0.99) 1.03 (1.00 to 1.06)
P value for trend‡ 0.008 0.034
Models were stratified by centre and sex, and systematic adjustment was undertaken for age at recruitment, 
body mass index, height, physical activity, smoking status, and history of hypertension. Analyses were conducted 
among participants with available information on lifetime alcohol intake.
*Defined as lifetime drinkers who were non-drinkers at baseline.
†P value for the Wald test statistics compared with a χ2 distribution with four degrees of freedom, not including the 
categories of former and never drinkers.
‡P value for lifetime alcohol consumption modelled as continuous variable, with inclusion in the model of an 
indicator variable expressing alcohol consumption, and exclusion of former drinkers.
Table 4 | Number of events and hazard ratios for non-fatal coronary heart disease 
(CHD) and non-fatal stroke by levels of types of alcohol consumption at baseline (g/
day)
Characteristic
Wine intake Beer intake
Events Hazard ratio (95% CI) Events Hazard ratio (95% CI)
Non-fatal CHD
Non-drinkers 2932 1.14 (1.03 to 1.25) 4021 1.08 (0.98 to 1.18)
0.1-2.9 2823 1 (ref) 2733 1 (ref)
3.0-9.9 1869 0.86 (0.77 to 0.93) 1611 1.07 (0.97 to 1.19)
10.0-19.9 649 0.86 (0.75 to 0.98) 473 0.98 (0.84 to 1.15)
20.0-39.9 686 0.76 (0.66 to 0.86) 317 0.86 (0.71 to 1.04)
≥40.0 348 0.73 (0.61 to 0.87) 152 0.79 (0.59 to 1.05)
P value* <0.001 0.069
12 g/day increase 0.94 (0.91 to 0.97) 0.94 (0.89 to 0.99)
P value for trend† <0.001 0.013
Non-fatal stroke
Non-drinkers 1764 1.13 (1.01 to 1.25) 2094 1.14 (1.03 to 1.26)
0.1-2.9 1671 1 (ref) 1829 1 (ref)
3.0-9.9 1398 0.95 (0.85 to 1.05) 1167 1.21 (1.08 to 1.35)
10.0-19.9 391 1.00 (0.85 to 1.16) 369 1.16 (0.98 to 1.37)
20.0-39.9 436 1.01 (0.87 to 1.17) 248 1.31 (1.07 to 1.60)
≥40.0 195 1.05 (0.84 to 1.30) 148 1.40 (1.06 to 1.84)
P value* 0.762 0.002
12 g/day increase 1.03 (0.99 to 1.07) 1.07 (1.03 to 1.12)
P value for trend† 0.204 0.002
Models were mutually adjusted for wine, beer, spirits, and fortified wine, and stratified by centre and sex, 
and systematic adjustment was undertaken for age at recruitment, body mass index, height, physical activity, 
smoking status, and history of hypertension. Models for wine and beer consumptions were mutually adjusted, 
and also included spirits, liquors, and fortified wine consumption.
*P value for the Wald test statistics compared with a χ2 distribution with four degrees of freedom, not including 
the category of alcohol subtype non-drinkers (<0.1 g/day).
†P value for types of alcohol at baseline modelled as a linear variable, with inclusion in the model of indicator 
variables expressing alcohol subtype consumption.
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Conclusions
Alcohol intake was inversely associated with the risk 
of non-fatal CHD but positively associated with the risk 
of different stroke subtypes, highlighting the opposing 
associations of alcohol intake with different CVD types. 
Given previous knowledge about alcohol intake’s 
positive association with all cause mortality and the 
risk of cancer, our results strengthen policies to reduce 
alcohol consumption. 
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